How Novo Nordisk Conquered the Obesity Market

Episode notes

In this episode of The CEO Diary, Lucas and Luna explore how Novo Nordisk transformed from a century-old Danish insulin maker into the world's most valuable pharmaceutical company, driven by its GLP-1 drugs Ozempic and Wegovy. They trace the strategic decisions by CEO Lars Fruergaard Jørgensen that turned a diabetes drug into a blockbuster weight-loss treatment, navigating supply shortages, pricing debates, and a massive manufacturing expansion. The hosts discuss how Novo Nordisk's 2025 market cap surpassed the entire Danish GDP, the company's $6.5 billion investment in new production facilities, and the competitive threat from Eli Lilly's Zepbound. They also examine the broader implications for obesity care, including the potential for GLP-1s to reduce healthcare costs and the ethical questions around drug pricing. A focused look at how one company reshaped global health and the pharmaceutical industry. #NovoNordisk #Ozempic #Wegovy #GLP1 #ObesityDrugs #LarsFruergaardJørgensen #PharmaceuticalIndustry #WeightLoss #Diabetes #DrugPricing #EliLilly #Zepbound #Healthcare #Denmark #Biotech #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• The Future of Healthcare with Dr. David Shulkin, former Secretary of the United States Department of Veterans Affairs Part 2Pharma Sessions · on GLP-1 drugs89 / 100
• Breaking Open the Black Box: How Transparent PBMs Are Reshaping Pharmacy Benefits with Jake Frenz, Founder & CEO of SmithRxThe Benefits Playbook · on GLP-1 drugs83 / 100
• Vital Signs - Healthcare Trends, Challenges and InnovationsThe Financial Executives Edge · on GLP-1 drugs83 / 100
• How to Use an Operations Mindset to Scale Product DeliveryThe Product Manager · on GLP-1 drugs81 / 100
• OUT OF SCOPE, Ep. 1: Hot Takes Roundtable with Tori Pastore (Soup) and Austin Campbell (Zero Knowledge)Validated · on GLP-1 drugs80 / 100
• Episode 124: Annie Lamont on Healthcare, AI, Epic, Medicaid, and the Future of American MedicineThe Puck: Venture Capital and Beyond · on GLP-1 drugs79 / 100

• How the CEO of Seven-Eleven Japan Rethought Convenience54 / 100
• How Patagonia Proved Purpose Pays Dividends
• How Satya Nadella Changed Microsofts Culture First
• How the CEO of a Family Firm Kept It Private Through a Century of Change
• How the CEO of Nvidia Sped Up the Chip Race